BACM
MDGL icon

Blue Arrow Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Blue Arrow Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,712
Closed -$388K – 164
2015
Q1 		$388K Buy
+5,712
New +$490K 0.04% 149

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blue Arrow Capital Management's MDGL Position: Q2 2015 in Review

Blue Arrow Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2015, closing a stake of 5,712 shares — an estimated $388K sold.

Blue Arrow Capital Management first reported a position in MDGL in Q1 2015 and held it in 1 quarter. The position peaked at $388K in Q1 2015. 97 funds tracked by Wall St. Rank hold MDGL as of Q2 2015.

  • Blue Arrow Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Blue Arrow Capital Management sold 5,712 Madrigal Pharmaceuticals shares in Q2 2015, an estimated $388K.
  • Blue Arrow Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Blue Arrow Capital Management's Madrigal Pharmaceuticals position peaked at $388K in Q1 2015.
  • 97 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2015.

Based on Blue Arrow Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.